Drug Trial Radar · NCT03862807
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 27, 2019
Primary completion
Oct 6, 2020
Study completion Oct 20, 2020
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Mar 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
Conditions
- Amyloidosis, Familial
- Transthyretin Amyloidosis
Interventions
PatisiranDrug
Patisiran was administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR)Time frame: Baseline, Months 6 and 12
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Créteil, France
Clinical Trial Site
Le Kremlin-Bicêtre, France
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Messina, Italy
Clinical Trial Site
Porto, Portugal
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
Huelva, Spain
Clinical Trial Site
Umeå, Sweden
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.